Solithromycin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Solithromycin
- DrugBank Accession Number
- DB09308
- Background
Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Solithromycin (DB09308)
- Weight
- Average: 845.0088
Monoisotopic: 844.474620535 - Chemical Formula
- C43H65FN6O10
- Synonyms
- Solithromycin
- External IDs
- CEM 101
- CEM-101
- OP 1068
- OP-1068
Pharmacology
- Indication
Investigated for the treatment of community-acquired pneumonia (CAP).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The metabolism of Abemaciclib can be decreased when combined with Solithromycin. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Solithromycin. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Solithromycin. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Solithromycin. Albendazole The metabolism of Albendazole can be decreased when combined with Solithromycin. Alectinib The metabolism of Alectinib can be decreased when combined with Solithromycin. Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Solithromycin. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Solithromycin. Alpelisib The metabolism of Alpelisib can be decreased when combined with Solithromycin. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Solithromycin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- J01FA16 — Solithromycin
- Drug Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Ketolides
- Lactones
- Macrolides
- Macrolides, Lincosamides and Streptogramins
- Polyketides
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminoglycosides
- Alternative Parents
- Phenyl-1,2,3-triazoles / Aniline and substituted anilines / Oxazolidinones / Oxanes / Alpha-haloketones / Carbamate esters / Heteroaromatic compounds / 1,2-aminoalcohols / Trialkylamines / Secondary alcohols show 15 more
- Substituents
- 1,2,3-triazole / 1,2-aminoalcohol / Acetal / Alcohol / Alkyl fluoride / Alkyl halide / Alpha-haloketone / Amine / Amino acid or derivatives / Aminoglycoside core show 37 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9U1ETH79CK
- CAS number
- 760981-83-7
- InChI Key
- IXXFZUPTQVDPPK-ZAWHAJPISA-N
- InChI
- InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
- IUPAC Name
- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyl-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone
- SMILES
- [H][C@]12N(CCCCN3C=C(N=N3)C3=CC(N)=CC=C3)C(=O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@@](C)(F)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OC
References
- General References
- Reinert RR: Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother. 2004 Jun;53(6):918-27. Epub 2004 Apr 29. [Article]
- Menache D: Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol. 1991 Jan;28(1):31-8. [Article]
- Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN: Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7. [Article]
- McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC: In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010 Jan;54(1):230-8. doi: 10.1128/AAC.01123-09. Epub 2009 Nov 2. [Article]
- Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN: CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2010 Apr;66(4):393-401. doi: 10.1016/j.diagmicrobio.2009.10.013. [Article]
- Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M: Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021. [Article]
- Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS: Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010 Dec;54(12):4961-70. doi: 10.1128/AAC.00860-10. Epub 2010 Sep 20. [Article]
- External Links
- PubChem Compound
- 25242512
- PubChem Substance
- 310265196
- ChemSpider
- 25056854
- ChEMBL
- CHEMBL1232510
- ZINC
- ZINC000095627834
- PDBe Ligand
- EM1
- Wikipedia
- Solithromycin
- PDB Entries
- 4www
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Community-Acquired Bacterial Pneumonia (CABP) 2 3 Completed Treatment Uncomplicated Urogenital Gonorrhea 1 2 Completed Treatment Community-Acquired Bacterial Pneumonia (CABP) 1 2 Completed Treatment Non Alcoholic Steatohepatitis (NASH) 1 2 Completed Treatment Uncomplicated Urogenital Gonorrhea 1 2 Terminated Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 2, 3 Terminated Treatment Community-Acquired Bacterial Pneumonia (CABP) 1 1 Completed Treatment Bacterial Infections 2 1 Completed Treatment Gonorrhoea 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0167 mg/mL ALOGPS logP 4.22 ALOGPS logP 5.76 ChemAxon logS -4.7 ALOGPS pKa (Strongest Acidic) 12.8 ChemAxon pKa (Strongest Basic) 7.68 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 12 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 197.87 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 230.73 m3·mol-1 ChemAxon Polarizability 90.81 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created on November 12, 2015 16:46 / Updated on February 21, 2021 18:52